Tesamorelin at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Tesamorelin (brand name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog. It is FDA-approved for the treatment of HIV-associated lipodystrophy, a condition characterized by excess abdominal fat accumulation in HIV patients on antiretroviral therapy.
Unlike synthetic HGH, tesamorelin works by stimulating the pituitary gland to produce and release growth hormone naturally. This results in a more physiological pattern of GH release, with preserved feedback mechanisms. Clinical trials have demonstrated significant reductions in visceral adipose tissue (VAT) with tesamorelin treatment.
Beyond its approved use, tesamorelin has attracted interest in the anti-aging and body composition optimization communities. Its ability to reduce dangerous visceral fat while maintaining muscle mass makes it particularly appealing for metabolic health optimization.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.